MAYO CLINIC

Jupiter Bioventures, co-founded by Nathaniel David and Norman Sharpless, raises $70 million to establish a biotech foundry focusing on cancer and disease areas. The foundry aims to validate scientific projects ('Moons') before scaling them into independent companies, leveraging a 'science first' model to reduce risk and improve patient outcomes.

Tanios S. Bekaii-Saab discusses the role of liquid biopsies in GI cancer diagnosis, highlighting their importance in cases where tissue availability is limited or delayed. Liquid biopsies assess circulating tumor DNA (ctDNA) and can detect genetic alterations like fusions, aiding early treatment decisions. They offer a non-invasive alternative to tissue biopsies, facilitating patient access to targeted therapies and monitoring tumor heterogeneity over time.

Jupiter Bioventures, co-founded by Nathaniel David and Norman Sharpless, raised $70 million to establish a biotech foundry focusing on cancer and disease areas. The financing includes Mission BioCapital, Mayo Clinic, and other investors. Jupiter aims to validate science early to reduce risk and build high-value biotech companies.

Echo IQ (ASX:EIQ) signed an integration agreement with top US cardiology hospital Beth Israel Deaconess Medical Center, leveraging its FDA-cleared AI-powered algorithm for heart disease detection. This deal, following FDA clearance, positions EIQ for significant industry exposure and potential revenue generation, with further hospital partnerships anticipated. EIQ's technology targets aortic stenosis and heart failure, with reimbursement from insurance companies forming its revenue model. The company is also in advanced negotiations with the prestigious Mayo Clinic for clinical validation of its heart failure product.

Cardiol Therapeutics announced positive Phase II MAvERIC-Pilot study results for CardiolRx in treating pericarditis, with sustained pain and inflammation reduction over 26 weeks, supporting upcoming Phase III trials.

Cardiol Therapeutics reports positive Phase II MAvERIC-Pilot study results showing CardiolRx™ maintained improvements in pericarditis pain and inflammation over 26 weeks. These findings support the initiation of Phase III trials, MAVERIC-3 and MAVERIC-2, to assess CardiolRx™ for pericarditis treatment and recurrence prevention.

Cardiol Therapeutics reported positive Phase II MAvERIC-Pilot results for CardiolRx™ in treating recurrent pericarditis, showing marked improvements in pain and inflammation maintained throughout the 26-week study, with key results including pain reduction from 5.8 to 1.5 at week 26, CRP normalization in 80% of patients at week 8, and reduction in pericarditis episodes from 5.8 to 0.9 per year, supporting advancement to Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials.

Prenetics, in partnership with David Beckham, launches IM8, a health and wellness brand with two premium products: Daily Ultimate Essentials and Daily Ultimate Longevity, available at IM8health.com, shipping to 31 countries. IM8 products are clinically proven, third-party tested, and designed to support daily health and long-term vitality.